News und Analysen
Why Ultragenyx Pharmaceutical Stock Is Sinking Today
Shares of the rare-disease drugmaker Ultragenyx Pharmaceutical (NASDAQ: RARE) are under pressure today after the company announced that its late-stage study assessing aceneuramic acid extended....
Why Tenet Healthcare Shares Are Rallying 14.2% Today
After a sell-off that's seen its shares drop from over $20 in July to below $13 earlier this month, news that a hedge fund has acquired a 5.7% stake sent shares of Tenet Healthcare (NYSE:....
A Record Number of Americans Have Tried Marijuana, New Survey Shows
Marijuana: it was once a taboo topic, but is no longer.According to a newly released study from national pollster Gallup, more Americans than ever have tried marijuana.Gallup has been sporadically....
Why Calpine, Tenet Healthcare, and Snap Jumped Today
Stocks closed down on Friday, as major benchmarks failed to make back lost ground from Thursday's steep declines. The departure of Trump administration chief strategist Stephen Bannon marked the....
Why Molina Healthcare, China Lodging Group, and U.S. Silica Holdings Jumped Today
The stock market fell sharply on Thursday, with major benchmarks finishing the day down between 1% and 2%. A terrorist attack in Barcelona reminded investors of the numerous geopolitical threats
Here's Why Horizon Pharma Gained as Much as 13.1% Today
Shares of rare disease biopharma Horizon Pharma (NASDAQ: HZNP) surged over 13% today after the law firm of Green, Griffith successfully asserted one of the company's patents covering Pennsaid 2%
Opko Health's Biggest Believer: CEO Phillip Frost Puts His Money Where His Mouth Is
Opko Health (NASDAQ: OPK) stock is down more than 30% so far in 2017. Its share price dropped 7% last year. But if you think the poor performance has caused the company's largest investor to lose
Up in Smoke: This Marijuana Stock Lost More Than Half Its Value Last Week
As a whole, marijuana stocks are on fire. Through about mid-July, the average marijuana stock was up over 300% on a trailing-12-month basis, albeit one stock with a 2,363% gain at the time had skewed
2 Marijuana Stocks That Turned $10,000 Into $125,000 and $300,000, Respectively
When it comes to top-performing industries, you'd have a tough time surpassing the returns of marijuana stocks. Of the 13 marijuana stocks with a market cap in excess of $200 million, over half have
Better Buy: Exact Sciences Corporation vs. Opko Health
"It was the best of times, it was the worst of times..."Charles Dickens wasn't referring to Exact Sciences (NASDAQ: EXAS) and Opko Health (NASDAQ: OPK) when he wrote those words, but they're certainly
Why Pan American Silver, Chefs' Warehouse, and Perrigo Jumped Today
Thursday was one of the worst sessions that the stock market has seen in several months, with major benchmarks falling 1% or more. Investors are growing increasingly nervous about the rising tensions
Here's Why Perrigo Company Rose as Much as 20.5% Today
Shares of Perrigo Company (NYSE: PRGO) rose over 20% this morning after the healthcare leader released second-quarter 2017 financial results and adjusted full-year 2017 guidance. While revenue slipped
5 Reasons Valeant's Situation Could Get Worse
Valeant Pharmaceuticals (NYSE: VRX) announced some good news in its second-quarter update on Tuesday. The drugmaker now expects to cut its debt by $5 billion sooner than its previous target of
Earnings Hangover Sacks Valeant Pharmaceuticals' Stock, Sending Shares Down 10%
Shares of embattled drugmaker Valeant Pharmaceuticals (NYSE: VRX) are pulling an about-face after initially moving higher following the release of its second-quarter earnings results before the
The Sole Reason Amicus Therapeutics, Inc. Exploded 29% Higher in July
Shares of Amicus Therapeutics (NASDAQ: FOLD), a biopharmaceutical company focused on the development rare-disease drugs, exploded higher by 29% during the month of July, according to data from S&P
The 1 Very Clear Reason Arena Pharmaceuticals, Inc. Skyrocketed 41% in July
Shares of Arena Pharmaceuticals (NASDAQ: ARNA), a biopharmaceutical company focused on the development of small-molecule drugs for the treatment of a variety of diseases, catapulted 41% during July
Here's Why Acadia Pharmaceuticals Inc. Is Soaring Today
In response to Acadia Pharmaceuticals (NASDAQ: ACAD) reporting blow-out earnings and sharing upbeat guidance, shares of the commercial-stage biopharma, which focuses on diseases of the central nervous
Finally! 3 Figures From Valeant's Second-Quarter Report That Demonstrate Improvement
If you've ever played the board game Chutes and Ladders and landed on space 87, which throws the player back 63 spaces, you might have some idea of what it's been like to be a Valeant Pharmaceuticals
Paion präsentiert Halbjahreszahlen – Überraschungen bleiben aus
Das Biotech-Unternehmen Paion hat heute die mit Spannung erwarteten Zahlen für die erste Jahreshälfte 2017 vorgelegt. Die aber schnell nachließ, denn wirklich Überraschendes wurde nicht....
Why Amedisys Shares Slumped 24.6% in July
Amedisys Inc. (NASDAQ: AMED) shares lost nearly 25% of their value last month, according to S&P Global Market Intelligence. The drop was caused by word that the the federal government's Centers for
Why Tenet Healthcare Shares Dropped 14.4% Today
After reporting second-quarter earnings and offering up guidance for 2017, shares of Tenet Healthcare (NYSE: THC) have fallen 14.6% as of 2:30 p.m. EDT on Tuesday.Tenet Healthcare's year-over-year
Why Avis Budget Group, Depomed, and Tenet Healthcare Slumped Today
Investors saw the end of a historic bullish streak for stocks on Tuesday, as the Dow Jones Industrials failed in their bid for a 10th straight day of record-setting gains. Instead, major benchmarks
MyoKardia Inc. Is on the Rise Again Today -- Here's Why
After a monster run-up on Monday, MyoKardia Inc. (NASDAQ: MYOK) climbed another 145.9% as of 3:30 p.m. during Tuesday's session. It seems investors still giddy about positive clinical trial data
Why FibroGen Inc Skyrocketed Higher Today
FibroGen (NASDAQ: FGEN) is up nearly 50% at 1:10 p.m. Tuesday after releasing positive data from its phase 2 trial testing pamrevlumab in patients with a lung disease called idiopathic pulmonary
Here's Why Valeant Pharmaceuticals Intl. Inc. Surged as Much as 10%
Shares of Valeant Pharmaceuticals (NYSE: VRX), the embattled drugmaker that's traditionally grown through acquisitions and price hikes over the years, surged as much as 10% during Tuesday's trading